Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johns Hopkins

This article was originally published in The Tan Sheet

Executive Summary

List of clinical trials that must be halted or reviewed due to HHS Office of Human Research Protections degree will be available by Aug. 10, university says. OHRP ruled July 19 that all human studies must be suspended after healthy patient died in trial June 2. However, office approved a corrective action plan July 21 that permits only human research studies eligible for expedited review, that were reviewed and approved in past year or that are ongoing and "in the best interests of the individual subjects" to resume. In October, NCCAM granted $7.8 mil. over five years to fund Hopkins Center for Complementary & Alternative Medicine in Cancer. JHU researchers also were conducting trials on OTC drugs and dietary supplements, including four-year study on glucosamine, chondrotin and knee osteoarthritis. Until list is released Aug. 10, it remains unclear whether these trials will be affected by OHRP/Hopkins compromise

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts